home / stock / bct:cc / bct:cc news

BCT:CC News and Press, Briacell Therapeutics Corp. From 10/25/23

Stock Information
Company Name: Briacell Therapeutics Corp.
Stock Symbol: BCT:CC
Market: TSXC
Website: briacell.com
Menu
BCT:CC BCT:CC Quote BCT:CC Short BCT:CC News BCT:CC Articles BCT:CC Message Board
Get BCT:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BCT:CC - BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
BCT:CC - October is Breast Cancer Awareness Month - BriaCell is Leading the Fight with its Innovative Technology

According to American Cancer Society Facts and Figures, breast cancer is the most common cancer in the United States with 300,590 expected new cases in 2023 43,700 women and men are expected to die of breast cancer in the U.S. in 2023, making breast cancer the 2nd leading cause of can...

BCT:CC - BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...

BCT:CC - BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT(TM) Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic

Dr. Adam M. Brufsky of University of Pittsburgh School of Medicine and Dr. Saranya Chumsri of Mayo Clinic will discuss the current treatment landscape for patients with advanced metastatic breast cancer and the latest clinical data of the Bria-IMT™ regimen BriaCell recently rep...
BCT:CC - BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast Cancer

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform canc...

BCT:CC - BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or physician’s choice therapy (1:1) Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria...

BCT:CC - Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

2023-09-13 09:00:30 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group –  Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food and Drug Administr...
BCT:CC - BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

Median overall survival of 13.5 months in BriaCell’s advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature) 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's co...

BCT:CC - BriaCell Therapeutics Corp. Announces Closing of Plan of Arrangement Spinning Out BriaPro Therapeutics Corp. to Existing Shareholders

BriaCell Therapeutics Corp. closes Arrangement effecting the distribution described in the plan of arrangement. TORONTO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (" BriaCell " or the " Company "), a clinical-stage biotechnology...

BCT:CC - BriaCell Accepts Letter of Intent from Weill Cornell Medicine Outlining Plans to Initiate a Clinical Trial of Bria-IMT(TM) in High-Risk Early-Stage Triple Negative Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer ca...
Previous 10 Next 10